in silico clinical trials

SBML2Modelica: Integrating biochemical models within open-standard simulation ecosystems

Motivation SBML is the most widespread language for the definition of biochemical models. Although dozens of SBML simulators are available, there is a general lack of support to the integration of SBML models within open-standard general-purpose simulation ecosystems. This hinders co-simulation and integration of SBML models within larger model networks, in order to, e.g. enable in silico clinical trials of drugs, pharmacological protocols, or engineering artefacts such as biomedical devices against Virtual Physiological Human models.

Optimal Personalised Treatment Computation through In Silico Clinical Trials on Patient Digital Twins

In Silico Clinical Trials (ISCT), i.e., clinical experimental campaigns carried out by means of computer simulations, hold the promise to decrease time and cost for the safety and efficacy assessment of pharmacological treatments, reduce the need for animal and human testing, and enable precision medicine.

In silico clinical trials through AI and statistical model checking

A Virtual Patient (VP) is a computational model accounting for individualised (patho-) physiology and Pharmaco-Kinetics/Dynamics of relevant drugs. Availability of VPs is among the enabling technology for In Silico Clinical Trials. Here we shortly outline the state of the art as for VP generation and summarise our recent work on Artificial Intelligence (AI) and Statistical Model Checking based generation of VPs.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma